Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

HER2-positive breast cancer accounts for 20–30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of trastuzumab in 1998 has significantly improved ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

MANILA, Philippines — The night sky over SM Mall of Asia (MOA) is set to come alive with breathtaking colors and music as the 12th Philippine International Pyromusical Competition (PIPC ...

The camp will end with the exhibition match involving Filipinas players to be held at the newly-completed MOA Football Field, a rare opportunity for the Filipino fans to watch the team at home.

Known as fam-trastuzumab deruxtecan but marketed under the brand name Enhertu, it is meant to treat advanced breast cancer that is HR-positive and HER2-low or ultralow, which has not improved ...